What technology is Rohto Pharmaceutical deploying in Hada Labo products as part of its longevity science initiative?

Rohto Pharmaceutical is deploying 'Phyto-exosome' technology in Hada Labo products based on plant and algae research.

Which specific Rohto Pharmaceutical brands will receive Phyto-exosome technology by 2024?

Hada Labo, Melano CC, and Obagi are the specific Rohto brands to receive Phyto-exosome technology.

How does Rohto Pharmaceutical's Phyto-exosome technology relate to cell research in 2024?

Phyto-exosome technology is based on Rohto's long-standing cell science research focused on plant and microbial cells.

What is the primary scientific basis for Rohto's longevity initiative launched in 2024?

The primary basis is Rohto's long-standing cell science research, now applied through Phyto-exosome technology.

When did Rohto Pharmaceutical announce the deployment of Phyto-exosome technology in Obagi products?

Rohto Pharmaceutical announced the deployment of Phyto-exosome technology in Obagi in 2024.

AI News NQ Analysis

Rohto Pharmaceutical Accelerates Social Implementation of 'Longevity' Science Based on Cell Research

NQ Score 88/100

N1 Content Completeness 90

Key facts

Rohto Pharmaceutical Accelerates Social Implementation of 'Longevity' Science Based on Cell Research
Rohto Pharmaceutical Co., Ltd. announced it will accelerate the social implementation of 'Longevity' science based on its long-standing cell science research. As the first phase, the company will sequentially deploy 'Phyto-exosome' technology, derived from plants, microorganisms, and algae, into its core skincare brands: 'Hada Labo', 'Melano CC', and 'Obagi'.
Source: PR TIMES
Date: Fri May 29 2026 20:00:02 GMT+0900 (Japan Standard Time)

Direct answer

Rohto Pharmaceutical Co., Ltd. announced it will accelerate the social implementation of 'Longevity' science based on its long-standing cell science research. As the first phase, the company will sequentially deploy 'Phyto-exosome' technology, derived from plants, microorganisms, and algae, into its core skincare brands: 'Hada Labo', 'Melano CC', and 'Obagi'.

Citation: Rohto Pharmaceutical Accelerates Social Implementation of 'Longevity' Science Based on Cell Research (Fri May 29 2026 20:00:02 GMT+0900 (Japan Standard Time)), PR TIMES
Source: PR TIMES
Date: Fri May 29 2026 20:00:02 GMT+0900 (Japan Standard Time)

AI Summary (NQ-processed)

Rohto Pharmaceutical Co., Ltd. announced it will accelerate the social implementation of 'Longevity' science based on its long-standing cell science research. As the first phase, the company will sequentially deploy 'Phyto-exosome' technology, derived from plants, microorganisms, and algae, into its core skincare brands: 'Hada Labo', 'Melano CC', and 'Obagi'.

AI Analysis

Frequently Asked Questions

Q: What technology is Rohto Pharmaceutical deploying in Hada Labo products as part of its longevity science initiative?: A: Rohto Pharmaceutical is deploying 'Phyto-exosome' technology in Hada Labo products based on plant and algae research.
Q: Which specific Rohto Pharmaceutical brands will receive Phyto-exosome technology by 2024?: A: Hada Labo, Melano CC, and Obagi are the specific Rohto brands to receive Phyto-exosome technology.
Q: How does Rohto Pharmaceutical's Phyto-exosome technology relate to cell research in 2024?: A: Phyto-exosome technology is based on Rohto's long-standing cell science research focused on plant and microbial cells.
Q: What is the primary scientific basis for Rohto's longevity initiative launched in 2024?: A: The primary basis is Rohto's long-standing cell science research, now applied through Phyto-exosome technology.
Q: When did Rohto Pharmaceutical announce the deployment of Phyto-exosome technology in Obagi products?: A: Rohto Pharmaceutical announced the deployment of Phyto-exosome technology in Obagi in 2024.